Latent Class Analysis of Perceived Stigma Among Older Adults Receiving Medications for Opioid Use Disorder

Overview

Journal J Subst Use Addict Treat

Specialty Psychiatry

Date 2023 Oct 20

PMID 37858796

Authors

Mary M Mitchell

Sahil Angelo

Olusegun G Akinwolere

Molly M Perkins

Alexis A Bender

Affiliations

Soon will be listed here.

Abstract

Rationale: Public stigma surrounds individuals who use medication for their recovery from a substance use disorder. However, we know little about subgroups of individuals with varying levels of perceived stigma and how these levels may be associated with physical and mental health-related quality of life (HRQOL) and social support.

Methods: We used latent class analysis to define subgroups of people aged 50-72 years of age (N = 104) who were enrolled in eight medication for opioid use disorder (MOUD) programs to explore subgroupings and correlates of group membership.

Results: We found evidence for three distinct classes of individuals and named the classes 1) the high stigma class, 2) the embarrassed class, and 3) the low stigma class. We found that people in the high-stigma class reported more rejection, more abstinence-based support group involvement, and reduced mental HRQOL.

Conclusions: Results suggest reducing stigma among people on MOUD may help to boost mental HRQOL and improve social support receipt. The results are consistent with iatrogenic effects of AA/NA support groups such that these treatment modalities may increase stigma due to their focus on abstinence-only treatment for substance use disorders.

References

Ware Jr J, Kosinski M, Keller S . A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-33. DOI: 10.1097/00005650-199603000-00003. View

Scorsone K, Haozous E, Hayes L, Cox K . Overcoming Barriers: Individual Experiences Obtaining Medication-Assisted Treatment for Opioid Use Disorder. Qual Health Res. 2020; 30(13):2103-2117. DOI: 10.1177/1049732320938689. View

Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko M, Filippovych S . Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug Alcohol Depend. 2016; 165:213-20. PMC: 5094181. DOI: 10.1016/j.drugalcdep.2016.06.011. View

Wakeman S, Rich J . Barriers to Medications for Addiction Treatment: How Stigma Kills. Subst Use Misuse. 2017; 53(2):330-333. DOI: 10.1080/10826084.2017.1363238. View

McElrath K, Joseph H . Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue. Subst Use Misuse. 2017; 53(2):177-180. DOI: 10.1080/10826084.2017.1404106. View

Lembke A, Zhang N . A qualitative study of treatment-seeking heroin users in contemporary China. Addict Sci Clin Pract. 2015; 10:23. PMC: 4672521. DOI: 10.1186/s13722-015-0044-3. View

Link B, STRUENING E, Rahav M, Phelan J, Nuttbrock L . On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav. 1997; 38(2):177-90. View

Madden E . Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019; 232:324-331. DOI: 10.1016/j.socscimed.2019.05.027. View

van Boekel L, Brouwers E, van Weeghel J, Garretsen H . Comparing stigmatising attitudes towards people with substance use disorders between the general public, GPs, mental health and addiction specialists and clients. Int J Soc Psychiatry. 2014; 61(6):539-49. DOI: 10.1177/0020764014562051. View

10.

Semple S, Grant I, Patterson T . Utilization of drug treatment programs by methamphetamine users: the role of social stigma. Am J Addict. 2005; 14(4):367-80. DOI: 10.1080/10550490591006924. View

11.

Cella D, Lai J, Nowinski C, Victorson D, Peterman A, Miller D . Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012; 78(23):1860-7. PMC: 3369516. DOI: 10.1212/WNL.0b013e318258f744. View

12.

Joseph H, Stancliff S, Langrod J . Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000; 67(5-6):347-64. View

13.

Olsen Y, Sharfstein J . Confronting the stigma of opioid use disorder--and its treatment. JAMA. 2014; 311(14):1393-4. DOI: 10.1001/jama.2014.2147. View

14.

Kaplan L . Medication-assisted treatment for opioid use disorder. Nurse Pract. 2018; 44(3):10-12. DOI: 10.1097/01.NPR.0000550252.04526.79. View

15.

Earnshaw V, Smith L, Chaudoir S, Amico K, Copenhaver M . HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013; 17(5):1785-95. PMC: 3664141. DOI: 10.1007/s10461-013-0437-9. View

16.

Paquette C, Syvertsen J, Pollini R . Stigma at every turn: Health services experiences among people who inject drugs. Int J Drug Policy. 2018; 57:104-110. PMC: 5994194. DOI: 10.1016/j.drugpo.2018.04.004. View

17.

Bozinoff N, Anderson B, Bailey G, Stein M . Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification. J Addict Med. 2017; 12(1):19-23. PMC: 5786480. DOI: 10.1097/ADM.0000000000000355. View

18.

Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R . Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug Alcohol Depend. 2018; 190:82-88. PMC: 6292439. DOI: 10.1016/j.drugalcdep.2018.05.027. View

19.

Witte T, Jaiswal J, Mumba M, Mugoya G . Stigma Surrounding the Use of Medically Assisted Treatment for Opioid Use Disorder. Subst Use Misuse. 2021; 56(10):1467-1475. DOI: 10.1080/10826084.2021.1936051. View

20.

Clark R, Baxter J, Aweh G, OConnell E, Fisher W, Barton B . Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. J Subst Abuse Treat. 2015; 57:75-80. PMC: 4560989. DOI: 10.1016/j.jsat.2015.05.001. View